Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Gene expression profiling of Lucilia sericata larvae extraction/secretion-treated skin wounds.

Authors: Polat, E  Aksoz, I  Arkan, H  Coskunpinar, E  Akbas, F  Onaran, I 
Citation: Polat E, etal., Gene. 2014 Oct 25;550(2):223-9. doi: 10.1016/j.gene.2014.08.033. Epub 2014 Aug 19.
Pubmed: (View Article at PubMed) PMID:25153915
DOI: Full-text: DOI:10.1016/j.gene.2014.08.033

The larvae of Lucilia sericata have been successfully used as medicinal maggots in the healing of wounds. The excretion/secretion (ES) products of the larvae have been shown to efficiently debride wounds and help the healing process. The mechanisms underlying ES-induced wound healing are not yet completely understood. One of the intriguing questions is the role of ESs in modulating gene expression at the transcriptional level in the skin wound environment during the healing process. To address this question, a study was conducted in which the ES-induced gene expression profile in wound biopsies and ES-treated wounds of rat skin in comparison with control group was analyzed at the molecular level by monitoring the expression of genes associated with wound healing. The expression levels of 82 genes at 4, 7, and 10 days after wounding were determined using a PCR array system following cDNA synthesis. A comparison from wounds revealed that 38 mRNAs (>/=5-fold expression) were differentially expressed in the ES-treated skin. For 27 genes, the multiple-test corrected p-value was statistically significant (p1000-fold) were Col1a2, Col4a1, Ctsk, Ccl7, Angpt1, Cd40lg, Egf and Itgb5. Several of these gene products might play key roles in ES-induced wound healing. These findings may provide new insight for an understanding of the therapeutic potential of ESs for wound healing.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 11352274
Created: 2016-07-13
Species: All species
Last Modified: 2016-07-13
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.